Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy
…, E Medda, C Ferrari, P Fabris, G Cariti… - Clinical infectious …, 2006 - academic.oup.com
Background . The epidemiology of acute hepatitis C has changed during the past decade in
Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when …
Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when …
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop
G Carosi, M Rizzetto, A Alberti, G Cariti… - Digestive and Liver …, 2011 - Elsevier
The Italian recommendations for the therapy of hepatitis B virus (HBV)-related disease were
issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was …
issued in 2008. Subsequently in 2008 the nucleotide analogue (NA) Tenofovir was …
Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease
…, MG Fallani, C Bussani, M Fambrini, G Cariti… - Archives of gynecology …, 2018 - Springer
Purpose To determine whether quadrivalent HPV vaccination is effective in reducing recurrent
disease in women with a previous history of HPV disease. Methods All women under 45 …
disease in women with a previous history of HPV disease. Methods All women under 45 …
Long-term reliability of fractioned CO2 laser as a treatment for vulvovaginal atrophy (VVA) symptoms
…, N Auzzi, A Becorpi, MG Fallani, G Cariti… - Archives of gynecology …, 2017 - Springer
Purpose The aim of this study was to evaluate long-term effects of the fractional CO 2 laser
for the treatment of vulvovaginal atrophy (VVA) symptoms. Methods Women presenting with …
for the treatment of vulvovaginal atrophy (VVA) symptoms. Methods Women presenting with …
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
…, A Bertoli, V Borghi, V Calvaruso, G Cariti… - Journal of …, 2021 - Elsevier
Background & Aims There are limited data on patients with chronic HCV infection in whom
combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, …
combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, …
Twelve-week treatment of acute hepatitis C virus with pegylated interferon-α-2b in injection drug users
…, S Audagnotto, S Garazzino, G Cariti… - Clinical infectious …, 2007 - academic.oup.com
Injection drug use is the leading risk factor for infection with hepatitis C virus, and interferon (IFN)
treatment in this context is associated with a poor rate of adherence. In this article, we …
treatment in this context is associated with a poor rate of adherence. In this article, we …
Treatment with direct‐acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study
…, A De Nicolò, J Cusato, G Cariti… - Journal of viral …, 2017 - Wiley Online Library
In this prospective study, we evaluated the effectiveness and tolerability of novel therapies
against hepatitis C virus ( HCV ) in a cohort of PWID enrolled at our centre from April 2015 to …
against hepatitis C virus ( HCV ) in a cohort of PWID enrolled at our centre from April 2015 to …
Kinetics and prediction of HB sAg loss during therapy with analogues in patients affected by chronic hepatitis B HB eAg negative and genotype D
L Boglione, A D'Avolio, G Cariti, G Gregori… - Liver …, 2013 - Wiley Online Library
Background & Aims In patients affected by chronic hepatitis because of HBV infection, long‐term
suppressive therapy with nucleos(t)ides analogues in the HBeAg− patients has shown …
suppressive therapy with nucleos(t)ides analogues in the HBeAg− patients has shown …
Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection
…, P Limone, B Forno, A Pollono, G Cariti… - European Journal of …, 1995 - academic.oup.com
Biglino A, Limone P, Forno B, Pollono A, Cariti G, Molinatti GM, Gioannini P. Altered
adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-I infection. Eur J …
adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-I infection. Eur J …
[HTML][HTML] Clinical effectiveness and pharmacokinetics of dalbavancin in treatment-experienced patients with skin, osteoarticular, or vascular infections
G Stroffolini, A De Nicolò, A Gaviraghi, J Mula, G Cariti… - Pharmaceutics, 2022 - mdpi.com
Dalbavancin (DBV) is a lipoglycopeptide approved for the treatment of Gram-positive
infections of the skin and skin-associated structures (ABSSSIs). Currently, its off-label use at …
infections of the skin and skin-associated structures (ABSSSIs). Currently, its off-label use at …